Pentixapharm Holding AG (ETR:PTP)

Market Cap	49.69M
Revenue (ttm)	137.00K
Net Income (ttm)	-16.86M
Shares Out	24.78M
EPS (ttm)	-0.68
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	19,189
Average Volume	22,765
Open	1.960
Previous Close	2.015
Day's Range	1.960 - 2.020
52-Week Range	1.904 - 5.150
Beta	n/a
RSI	44.10
Earnings Date	Aug 7, 2025

About Accolade

Pentixapharm Holding AG, a clinical-stage biopharmaceutical company, develops radiopharmaceuticals. The company focuses on developing CXCR4 ligand-based technology, which includes PentixaFor (PT-001), a tracer based on Gallium-68, used to diagnose and monitor the progress of various diseases, including hematological and solid tumors, as well as endocrine, cardiovascular, and immunological disorders; and PentixaTher (PT-002), a therapeutic radiopharmaceutical based on Yttrium-90 and Lutetium-177, for the treatment of leukemia, which is in Phase ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2019
• Employees: 75
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: PTP

Financial Performance

In 2024, Pentixapharm Holding AG's revenue was 1.40 million, a decrease of -78.47% compared to the previous year's 6.51 million. Losses were -13.98 million, 82.9% more than in 2023.